Artivion (NYSE:AORT) Price Target Cut to $42.00 by Analysts at Citizens Jmp

Artivion (NYSE:AORT) had its price objective lowered by Citizens Jmp from $48.00 to $42.00 in a research note published on Friday morning,Benzinga reports. The brokerage currently has a market outperform rating on the stock.

A number of other equities analysts have also issued reports on AORT. Citigroup reaffirmed a “market outperform” rating on shares of Artivion in a research note on Tuesday, July 21st. Canaccord Genuity Group dropped their price objective on Artivion from $40.00 to $30.00 and set a “buy” rating on the stock in a research note on Friday. Weiss Ratings lowered Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Needham & Company LLC reaffirmed a “buy” rating and set a $44.00 target price on shares of Artivion in a research note on Monday, July 20th. Finally, Jefferies Financial Group began coverage on Artivion in a report on Tuesday, October 20th. They set a “buy” rating and a $31.00 target price on the stock. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $39.00.

Artivion Stock Performance

AORT traded down $5.09 during trading hours on Friday, hitting $20.23. The company’s stock had a trading volume of 3,246,962 shares, compared to its average volume of 486,118. The company has a 50-day simple moving average of $23.55 and a 200 day simple moving average of $28.98. The company has a current ratio of 3.47, a quick ratio of 2.51 and a debt-to-equity ratio of 0.82. The firm has a market capitalization of $986.66 million, a PE ratio of -56.21 and a beta of 1.31. Artivion has a fifty-two week low of $19.16 and a fifty-two week high of $48.25.

Artivion (NYSE:AORT) last posted its quarterly earnings data on Thursday, November 5th. The company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.14. Artivion had a negative net margin of 0.67% and a positive return on equity of 6.07%. The business had revenue of $123.79 million during the quarter, compared to analysts’ expectations of $120.97 million. As a group, sell-side analysts expect that Artivion will post 0.45 EPS for the current year.

Insiders Place Their Bets

In other Artivion news, SVP Andrew Green sold 11,480 shares of the company’s stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $24.97, for a total value of $286,655.60. Following the transaction, the senior vice president owned 40,160 shares of the company’s stock, valued at approximately $1,002,795.20. This represents a 22.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO James Mackin sold 70,000 shares of the stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $28.95, for a total value of $2,026,500.00. Following the sale, the chief executive officer owned 877,275 shares of the company’s stock, valued at $25,397,111.25. This trade represents a 7.39% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 90,460 shares of company stock worth $2,557,366. 6.30% of the stock is owned by insiders.

Institutional Investors Weigh In On Artivion

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Rockefeller Capital Management L.P. lifted its holdings in shares of Artivion by 150.0% during the fourth quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company’s stock valued at $30,000 after purchasing an additional 399 shares during the last quarter. Allworth Financial LP boosted its position in shares of Artivion by 2,048.3% in the 3rd quarter. Allworth Financial LP now owns 1,246 shares of the company’s stock valued at $28,000 after purchasing an additional 1,188 shares during the period. Pinnacle Wealth Planning Services Inc. increased its stake in Artivion by 362.8% in the 3rd quarter. Pinnacle Wealth Planning Services Inc. now owns 1,379 shares of the company’s stock worth $31,000 after purchasing an additional 1,081 shares in the last quarter. Versant Capital Management Inc increased its stake in Artivion by 38.0% in the 3rd quarter. Versant Capital Management Inc now owns 2,119 shares of the company’s stock worth $48,000 after purchasing an additional 584 shares in the last quarter. Finally, Fulcrum Asset Management LLP purchased a new position in Artivion in the 3rd quarter worth about $49,000. 86.37% of the stock is owned by institutional investors and hedge funds.

Key Artivion News

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Q3 revenue rose 9% year over year to $123.8 million, exceeding analysts’ estimates of about $121 million. The company also reported non-GAAP EPS of $0.08, above a consensus estimate of a $0.06 loss cited in one report. Artivion Q3 results
• Positive Sentiment: Artivion forecast 2026 revenue of $484 million to $492 million and said it is preparing to launch its NEXUS product in January 2027, offering potential future growth catalysts. Revenue outlook and NEXUS launch
• Neutral Sentiment: Citizens JMP lowered its price target to $42 from $48 but maintained a Market Outperform rating; the revised target still implies substantial upside from the cited share price. Citizens JMP recommendations
• Negative Sentiment: Canaccord also cut its target, to $30, adding to concerns about analysts’ reassessment of the stock’s outlook. Canaccord price-target change
• Negative Sentiment: Despite revenue growth, Artivion posted a $7.9 million GAAP net loss, and adjusted EBITDA fell 8% to $22.5 million. Zacks also reported that the $0.08 quarterly EPS missed its $0.11 estimate, highlighting that earnings expectations vary by source and may weigh on sentiment. Zacks earnings analysis

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a medical device and biotechnology company focused on developing and commercializing products used in cardiac and vascular surgery. Its portfolio includes implantable devices, surgical sealants, and human tissue products designed to treat diseases of the heart, aorta, and peripheral blood vessels.

The company’s products include On-X mechanical heart valves, aortic and vascular grafts, BioGlue surgical adhesive, and stent graft systems for aortic repair. Artivion also provides tissue preservation services and distributes cardiac and vascular allografts for use in reconstructive procedures.

Artivion was formerly known as CryoLife, a company founded in 1984, and adopted the Artivion name in 2021 to reflect its broader focus on aortic and cardiac care.